Affini-T Therapeutics is a biotechnology company focused on developing TCR-based immunotherapies for the treatment of solid tumors. Utilizing two complementary therapeutic modalities, the company targets oncogenic driver mutations such as TP53 R175H and KRAS G12D/G12V. Affini-T Therapeutics is committed to advancing its pipeline programs to combat cancer and improve patient outcomes through innovative science and research.
51 - 200 employees
𧬠Biotechnology
βοΈ Healthcare Insurance
π Pharmaceuticals
π° $175M Venture Round on 2022-03
September 27
Lead clinical science activities at Affini-T Therapeutics to support clinical programs.
πΊπΈ United States β Remote
π° $175M Venture Round on 2022-03
β° Full Time
π Senior
π Director